- Home
- CYCC
as 07-26-2024 4:00pm EST
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 2.6M | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 61.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -22.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $11.40 | Next Earning Date: | 08-07-2024 |
| Revenue: | $449,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -85.55% | Revenue Growth (next year): | 68.07% |
Latest Cyclacel Pharmaceuticals Inc. News
CYCC Breaking Stock News: Dive into CYCC Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
MT Newswires
a month ago
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise
GlobeNewswire
a month ago
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Zacks
2 months ago
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
GlobeNewswire
2 months ago
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
GlobeNewswire
2 months ago
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
GuruFocus.com
2 months ago
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
GlobeNewswire
2 months ago
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
Compare CYCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYCC Cyclacel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.